↓ Skip to main content

A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains

Overview of attention for article published in Retrovirology: Research & Treatment, January 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#33 of 449)
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

blogs
1 blog
twitter
3 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
15 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains
Published in
Retrovirology: Research & Treatment, January 2012
DOI 10.1186/1742-4690-9-104
Pubmed ID
Authors

Lu, Chungen Pan, Yuan Li, Hong Lu, Wu He, Shibo Jiang

Abstract

Most currently approved anti-HIV drugs (e.g., reverse transcriptase inhibitors, protease inhibitors and fusion/entry inhibitors) must act inside or on surface of the target cell to inhibit HIV infection, but none can directly inactivate virions away from cells. Although soluble CD4 (sCD4) can inactivate laboratory-adapted HIV-1 strains, it fails to reduce the viral loads in clinical trials because of its low potency against primary isolates and tendency to enhance HIV-1 infection at low concentration. Thus, it is essential to design a better HIV inactivator with improved potency for developing new anti-HIV therapeutics that can actively attack the virus in the circulation before it attaches to and enter into the target cell.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 27%
Student > Ph. D. Student 4 27%
Professor 1 7%
Student > Doctoral Student 1 7%
Lecturer 1 7%
Other 3 20%
Unknown 1 7%
Readers by discipline Count As %
Agricultural and Biological Sciences 3 20%
Biochemistry, Genetics and Molecular Biology 2 13%
Chemistry 2 13%
Medicine and Dentistry 2 13%
Immunology and Microbiology 1 7%
Other 4 27%
Unknown 1 7%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 October 2014.
All research outputs
#784,227
of 8,029,773 outputs
Outputs from Retrovirology: Research & Treatment
#33
of 449 outputs
Outputs of similar age
#36,755
of 307,501 outputs
Outputs of similar age from Retrovirology: Research & Treatment
#2
of 26 outputs
Altmetric has tracked 8,029,773 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 449 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 307,501 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.